Centre proposes immediate suspension of licences for substandard drugs
The Health Ministry has introduced regulations to immediately suspend manufacturing licenses for medicines that fail quality criteria. These measures aim to stop substandard drugs from reaching patients. Suspension of licenses will occur based on the findings of government analysts. This action intends to limit the circulation of poor-quality medicine during regulatory reviews.
The Health Ministry has introduced new regulations aimed at suspending manufacturing licenses for medicines that do not meet quality criteria. This swift action is intended to stop subpar drugs from reaching patients and to minimize their circulation during the regulatory review. Licenses can be suspended based on government analysts' findings that indicate deficiencies.